Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Evolus, Inc.    EOLS

EVOLUS, INC.

(EOLS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/24/2020 11/25/2020 11/27/2020 11/30/2020 12/01/2020 Date
3.66(c) 3.76(c) 3.83(c) 3.73(c) 3.69 Last
445 984 494 208 189 548 339 778 222 289 Volume
-2.14% +2.73% +1.86% -2.61% -1.07% Change
More quotes
Financials (USD)
Sales 2020 57,9 M - -
Net income 2020 -65,6 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,92x
Yield 2020 -
Sales 2021 115 M - -
Net income 2021 -34,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,24x
Yield 2021 -
Capitalization 126 M 126 M -
Capi. / Sales 2020 2,17x
Capi. / Sales 2021 1,09x
Nbr of Employees 125
Free-Float 66,0%
More Financials
Company
Evolus, Inc. is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market. It offers physicians and... 
More about the company
Notations Surperformance© of Evolus, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about EVOLUS, INC.
11/24EVOLUS, INC. CLASS ACTION ALERT : Wolf Haldenstein Adler Freeman & Herz LLP remi..
PR
11/19EVOLUS, INC. : Regulation FD Disclosure (form 8-K)
AQ
11/14EVOLUS : ROSEN, A TOP RANKED LAW FIRM, Reminds Evolus, Inc. Investors of Importa..
PR
11/10SHAREHOLDER ALERT : Robbins LLP Is Investigating Evolus, Inc. (EOLS) on Behalf o..
BU
11/09DEADLINE REMINDER : Law Offices of Howard G. Smith Reminds Investors of Looming ..
PR
11/05GLANCY PRONGAY & MURRAY LLP : Reminds Investors of Looming Deadline in the Class..
PR
11/03EVOLUS : The Law Offices of Frank R. Cruz Announces the Filing of a Securities C..
PR
10/30EVOLUS : ROSEN, LEADING INVESTOR COUNSEL, Reminds Evolus, Inc. Investors of Impo..
PR
10/30EVOLUS : Announces Promotion of Michael Mazen Jafar to Chief Commercial Officer ..
AQ
10/30EVOLUS : Reports Third Quarter 2020 Results and Provides Business Update
AQ
10/30EVOLUS, INC. CLASS ACTION ALERT : Wolf Haldenstein Adler Freeman & Herz LLP anno..
PR
10/29EVOLUS : ROSEN, A TOP RANKED LAW FIRM, Reminds Evolus, Inc. Investors of Importa..
BU
10/29EVOLUS : Management's Discussion and Analysis of Financial Condition and Results..
AQ
10/29EVOLUS, INC. : Results of Operations and Financial Condition, Change in Director..
AQ
10/29EVOLUS : Announces Promotion of Michael Mazen Jafar to Chief Commercial Officer ..
AQ
More news
News in other languages on EVOLUS, INC.
2019WALL STREET STOCK EXCHANGE : Wall Street termine en hausse, soutenue par les tec..
2019Point marchés-Wall Street termine en hausse, soutenue par les techs (actualis..
2019WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
More news
Chart EVOLUS, INC.
Duration : Period :
Evolus, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOLUS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 7,14 $
Last Close Price 3,73 $
Spread / Highest target 249%
Spread / Average Target 91,5%
Spread / Lowest Target 7,24%
EPS Revisions
Managers
NameTitle
David Moatazedi President, Chief Executive Officer & Director
Vikram Malik Chairman
Alejandro Sabad Vice President-Operations
Lauren P. Silvernail Chief Financial & Accounting Officer
Rui Avelar Chief Medical Officer, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
EVOLUS, INC.-69.35%126
GILEAD SCIENCES, INC.-6.63%76 052
VERTEX PHARMACEUTICALS4.02%59 224
REGENERON PHARMACEUTICALS37.43%54 464
WUXI APPTEC CO., LTD.57.04%38 135
BIONTECH SE266.71%29 915